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SUMMARY
Background: Differences in risk factors for survival and
recurrence after liver resection for hepatocellular carci-
noma (HCC) in patients with or without cirrhosis are
not fully clarified.
Aim: To review a single-centre experience of curative
liver resections for HCC in order to evaluate clinico-
pathologic features and the long-term outcome of
cirrhotic and noncirrhotic patients.
Methods: From 1981 to 2002, 308 curative liver
resections for HCC on cirrhosis (Group 1) and 135 for
HCC without cirrhosis (Group 2) were performed. The
main demographic, clinicopathologic and operative
parameters, as well as early results were analysed and
compared. Overall and disease-free survival were evalu-
ated. Prognostic factors for survival and for tumour
recurrence were studied by univariate and multivariate
analysis.
Results: Group 1 had worse preoperative liver function
and higher frequency of hepatitis C virus infection. In
Group 2, HCC showed larger mean tumour diameter
(P < 0.001), poorer differentiation (P < 0.05) and
more frequent macrovascular invasion (P < 0.05).
Although more extended resections were performed
in Group 2 (P < 0.001), there were no differences in
blood transfusions, while post-operative complication
rate was higher in Group 1 (P < 0.005). After 1992,
in-hospital mortality was 2.9% in Group 1 and 1.1%
in Group 2 (P ¼ N.S.). The 3- and 5-year overall
survival was 63.7% and 42.2% in Group 1, and 67.9%
and 51% in Group 2 (P < 0.05). The 3- and 5-year
disease-free survival was 49.3% and 27.8% in Group
1, and 58% and 45.6% in Group 2 (P < 0.005).
Serum bilirubin level > 1.2 mg ⁄dL, multiple nodules,
micro and macrovascular invasion, diaphragm infiltra-
tion and blood transfusions independently affected
survival in Group 1. Blood replacement was the only
negative prognostic factor in Group 2. Independent
risk factors for tumour recurrence were satellite
nodules and resection performed before 1992 in Group
1, and age < 60 in Group 2.
Conclusions: Despite a more aggressive behaviour, HCC
without cirrhosis led to better overall and disease-free
survival compared to HCC with cirrhosis after curative
liver resection. Age and intra-operative blood transfu-
sions are the only predictors of outcome in patients
without cirrhosis. The impact of the latter on long-term
survival in both our groups outlines the importance of
surgical technique on the results of hepatectomies.
INTRODUCTION
Hepatocellular carcinoma (HCC) is one of the more
common malignancies and its frequency is increasing in
Western countries.1–3 For patients carrying tumours at
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an early stage and with a preserved hepatic function,
liver resection is the best therapeutic choice.
The recent improvements in preoperative selection of
patients, in surgical techniques and in post-operative
care yield very low operative mortality rates in the
most experienced centres.4–6 Furthermore, in the last
few years the same institutions have reported
increasing long-term results, with a 5-year survival
of around 50% or even higher.6, 7 In spite of this,
the rate of tumour recurrence after hepatectomy
remains high, ranging from 60% to 100% in the
long-term.7–11
Factors related to tumour recurrence and survival in
cirrhotic patients undergoing liver resection have
been extensively studied.7–15 In patients without
cirrhosis (i.e. those with chronic hepatitis or a
morphologically healthy liver), however, knowledge
on the variables with an impact on long-term
outcome and tumour recurrence is more limited,
with only a few studies addressing this issue reported
in the literature.16, 17
We retrospectively reviewed our experience of liver
resections for HCC in order to verify the differences in
clinicopathologic characteristics and outcome of
patients with and without cirrhosis. We also assessed
the influence of patient and tumour-related factors on
survival and recurrence of HCC in these two different
populations.
PATIENTS AND METHODS
From March 1981 to June 2002, a total of 443 curative
hepatic resections for HCC were performed at the
Department of Surgery and Transplantation, University
of Bologna, Italy. A resection was defined as curative
when it was possible to remove the entire neoplastic
mass with a histologically proven tumour-free surgical
margin. The results of most hepatectomies performed in
cirrhotic patients have been reported in an already
published report.6
The present series included 308 liver resections for
HCC on cirrhosis (69.5%, Group 1) and 135 liver
resections for HCC in noncirrhotic livers (30.5%, Group
2), considering in this latter group either patients
without liver fibrosis (n ¼ 68, 50.4%) or patients with
chronic hepatitis with fibrosis up to stage III18 (n ¼ 67,
49.6%). There were 339 males (76.5%) and 104
females (23.5%). Mean age was 62.3 ± 9.7 years
(ranging from 13 to 82 years).
Surgical treatment was indicated when the complete
removal of the tumour was considered possible, in
accordance with the volume of the remnant liver, the
technical feasibility (based on size and location of the
lesion) and the preoperative liver function, which was
assessed with the Child–Pugh score6 and subsequently
with the lignocaine (lidocaine) (MEGX) test.19
After discharge, patients were followed-up with dosage
of serum a-fetoprotein (AFP) level and hepatic ultraso-
nography every 3 months, and with chest X-ray every
6 months. In the case of suspected tumour recurrence,
abdominal computed tomography and ⁄or angiography
of the celiac trunk with Lipiodol injection and, if
necessary, liver biopsy was carried out.
The results for the treatment of tumour recurrence
have already been reported.6
End-points
The primary aim of this study was to examine and
compare demographic and clinicopathologic character-
istics, early results (in terms of in-hospital mortality and
complication rate), long-term survival and disease-free
survival of the two groups of patients. Secondarily,
factors with a possible impact on patient survival and
tumour recurrence were separately analysed in the two
study groups.
The following 21 variables were evaluated in a
univariate and multivariate analysis: sex, age, symp-
toms related to tumour mass-effect or rupture at
presentation, presence of ascites, total serum bilirubin
level, Child–Pugh score; aetiology (viral, alcoholic or
other), hepatitis B surface antigen (HBsAg) and anti-
hepatitis C antibodies (anti-HCV) status, AFP level;
tumour histological features (maximum tumour diam-
eter, number of nodules, presence of capsule, presence of
satellite nodules, micro and macrovascular invasion,
Edmonson’s grade of differentiation); liver resection
performed before 1992 or starting from 1992, type of
hepatectomy (wedge resection, resection of one or two
liver segments, or more than two liver segments,
according to the Couinuad’s classification20), dia-
phragm infiltration, and intra-operative packed red
blood cells consumption.
The year 1992 was chosen as the cut-off value because
the improvements in clinical assessment, surgical
technique, anaesthesiology support and post-operative
care were definitely introduced since that date, as
reported elsewhere.6
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Statistical analysis
Results were expressed as median ± standard deviation.
Differences between continuous and categorical vari-
ables were evaluated with the Student’s t-test and with
the v2 test, respectively. The Kaplan–Meier method was
used for the analysis of prognostic factors for patient
survival and disease-free survival, and the differences
between the groups were compared by the log-rank test.
Survival was considered from the day of surgery to the
day of death or the last follow-up visit. Recurrence rate
was computed from the day of surgery to the date of
detection of tumour recurrence. Disease-free survival
was computed by combining the two mentioned
variables, considering the date of death or the date of
tumour recurrence as the terminal events. Variables
achieving statistical significance at the univariate
analysis of survival were put in the multivariate
analysis, performed with the Cox’s proportional hazard
model. Variables with significant impact on tumour
recurrence at the univariate analysis were used in the
multivariate analysis with the Cox regression model. A
P-value < 0.05 was considered statistically significant.
Statistical analysis was carried out with the SPSS
software packaging (SPSS Inc., Chicago, IL).
RESULTS
Clinicopathologic profiles (Table 1)
Group 1 and Group 2 were comparable as regards sex
and age distribution, documented alcoholic habit, HBsAg
Table 1. Clinicopathologic profiles of cirrhotic and noncirrhotic patients
Cirrhotic patients (n ¼ 308) Noncirrhotic patients (n ¼ 135) P-value
Sex (M ⁄F) 239 ⁄69 100 ⁄35 N.S.
Age (years) 62 ± 8 (22–81) 62 ± 12 (13–82) N.S.
Alcoholic habit 67 (21.7%) 29 (21.5%) N.S.
Tumor-related symptoms 54 (17.5%) 69 (51.1%) < 0.001
Ascites 23 (7.5%) – < 0.001
Albumin level (g ⁄dL) 3.8 ± 0.4 (2–5.2) 4.0 ± 0.4 (2.9–5.1) < 0.001
Total bilirubin level (mg ⁄dL) 1.1 ± 0.6 (0.3–6.6) 0.9 ± 0.5 (0.3–4) < 0.001
Child-Pugh score
A 248 (80.5%) 125 (92.6%) < 0.01
B or C 60 (19.5%) 10 (7.4%)
Etiology
Viral 216 (70.1%) 47 (34.8%) < 0.001
Alcohol 11 (3.6%) 9 (6.7%)
Other 81 (26.3%) 79 (58.5%)
HBsAg+ 46 (14.9%) 17 (12.6%) N.S.
HCV+ 182 (56.8%) 33 (24.4%) < 0.001
a-fetoprotein (ng ⁄mL) 885 ± 7070 (1–105 000) 4374 ± 19 455 (1–130 000) N.S.
Maximum tumour diameter (cm) 4.3 ± 2.1 (0.5–15) 7.9 ± 4.6 (1.3–20) < 0.001
Number of nodules
Single 282 (91.6%) 118 (87.4%) N.S.
Multiple 26 (8.4%) 17 (12.6%)
Tumor capsule
Complete 111 (36%) 42 (31.1%) N.S.
Incomplete or absent 197 (64%) 93 (68.9%)
Satellite nodules
Present 46 (14.9%) 22 (16.3%) N.S.
Absent 262 (85.1%) 113 (83.7%)
Microvascular invasion
Present 154 (50%) 72 (53.3%) N.S.
Absent 154 (50%) 63 (46.7%)
Macrovascular invasion
Present 8 (2.6%) 11 (8.1%) < 0.05
Absent 300 (97.4%) 124 (91.9%)
Edmonson grade 3–4 168 (54.5%) 81 (60%) < 0.05
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status, mean preoperative AFP level, number of cases
with multiple nodules, absent or incomplete tumour
capsule, satellite nodules and microvascular thrombosis.
Conversely, noncirrhotic patients presented with
tumour-related symptoms in more than half of cases,
and with a tumour diameter larger than 5 cm in almost
60% of cases. Cirrhotics were usually diagnosed to carry
smaller HCCs during monitoring of liver disease.
There was a higher incidence of viral aetiology (70%)
and HCV+ patients (57%) in cirrhotic patients, whose
preoperative clinical conditions were significantly worse
than in noncirrhotic patients, resulting from higher
preoperative albumin and bilirubin levels, higher Child–
Pugh score and presence of ascites. In both groups the
number of patients belonging to Child C and B classes
was very low, according to our policy of selecting
patients with a normal liver function.6
Pathological features of HCC in noncirrhotic patients
were a lower tumour differentiation and a higher
incidence of macrovascular thrombosis compared to
cirrhotics.
Operative parameters and early results (Table 2)
Approximately two-thirds of surgical procedures were
carried out after 1992 in both groups.
Although the better hepatic function in patients of
Group 2 allowed the removal of a greater portion of liver
parenchyma, as a result of the higher proportion of
resection of more than two segments in this population
(45% of cases), the number of patients receiving intra-
operative packed red blood cells and fresh-frozen plasma
transfusions was similar. On the other hand, Group 1
patients more frequently experienced post-operative
complications (42% vs. 26% of cases), as expected by
the presence of cirrhosis. No significant differences were
observed in proportion of cases with diaphragm infil-
tration.
The post-operative hospital stay and the in-hospital
mortality rates were also similar. The in-hospital
mortality showed a clear decrease in the more recent
years in both study groups.
Patient survival, recurrence rate and disease-free survival
The median follow-up was 28.4 months (range: 0–241).
A total of 169 patients from Group 1 and 48 from Group 2
died (54.9% and 35.6%, respectively). The 1-, 3- and
5-year overall survival rates were 86.1%, 63.7% and
42.2% in Group 1, and 84%, 67.9% and 51% in Group 2,
respectively. Patient survival was significantly worse
(P < 0.05) in cirrhotic patients (Figure 1).
Table 2. Operative data and early outcome
of cirrhotic and noncirrhotic patients
Cirrhotic patients
(n ¼ 308)
Noncirrhotic patients
(n ¼ 135) P-value
Time of surgery
Before 1992 102 (33.1%) 44 (32.6%) N.S.
1992 or later 206 (66.9%) 91 (67.4%)
Type of resection
Wedge 108 (35.1%) 17 (12.8%) < 0.001
1–2 segments 176 (57.3%) 62 (45.9%)
> 2 segments 24 (7.8%) 56 (42.1%)
Anatomical resections
Yes 200 (64.9%) 117 (86.7%) < 0.001
No 108 (35.1%) 18 (13.3%)
Diaphragm infiltration 9 (2.9%) 8 (5.9%) N.S.
Packed red blood cells transfusions
Yes 116 (37.7%) 53 (39.2%) N.S.
No 192 (62.3%) 82 (60.7%)
Fresh-frozen plasma transfusions
Yes 106 (34.4%) 34 (25.2%) N.S.
No 202 (65.6%) 101 (74.8%)
Post-operative complications 129 (41.9%) 35 (25.9%) < 0.005
Hospital stay (days) 11 ± 23 (4–94) 10 ± 34 (4–64) N.S.
Hospital mortality 15 (4.9%) 4 (3.0%) N.S.
Hospital mortality after 1992 6 (2.9%) 1 (1.1%) N.S.
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Tumour recurrence was observed in 120 (39%)
patients from Group 1 and 41 (30.4%) patients from
Group 2 (P ¼ N.S.). For patients with a follow-up of at
least 1 year, tumour recurrence was the cause of death
in 75% of patients in Group 1 and 88.2% of patients in
Group 2.
The 1-, 3- and 5-year recurrence rates were 15.2%,
33.1% and 50.5% in Group 1, and 17.3%, 32.8% and
39.7% in Group 2, respectively (P ¼ N.S.). The 1-, 3-
and 5-year disease-free survival rates were 76%, 49.3%
and 27.8% in Group 1, and 77.6%, 58% and 45.6% in
Group 2, respectively (P < 0.005) (Figure 2).
In Group 2, 17 patients with chronic hepatitis (25.4%)
and 31 patients without chronic hepatitis died (45.6%).
The 1-, 3- and 5-year overall survival of these
subgroups of patients were almost significant in favour
of patients with chronic hepatitis (93%, 76.5% and
57.4% vs. 75.3%, 59.8% and 45.5%, respectively,
P ¼ 0.053).
For both groups, the 1-, 3- and 5-year overall survival
was significantly better for patients operated on in 1992
or later than for those operated on before 1992 (Group
1: 91.6%, 70.7% and 48.6% vs. 76.5%, 52.9% and
33.3%, P < 0.01; Group 2: 90.4%, 78.9% and 64.1%
vs. 72.7%, 52.3% and 36.4%, P < 0.005).
Univariate analysis of variables affecting overall survival
and tumour recurrence
By the univariate analysis, factors negatively affecting
survival in Group 1 were tumour-related symptoms at
presentation, presence of ascites, total serum bilirubin
> 1.2 mg ⁄dL, Child–Pugh score B or C, AFP level
> 20 ng ⁄mL, multiple nodules, absent or incomplete
capsule, presence of satellite nodules, macrovascular
and microvascular invasion, resection performed
before 1992, diaphragm infiltration, and necessity of
intra-operative blood transfusions. In Group 2, vari-
ables predicting poorer survival were tumour-related
symptoms, presence of satellite nodules, surgery before
1992, and intra-operative blood transfusions
(Table 3).
In Group 1, tumour recurrence was significantly
correlated with male sex, liver disease other than viral
or alcoholic, presence of satellite nodules, surgery
before 1992, and blood transfusions, while in Group 2
it was associated with age < 60 years, macrovascular
infiltration and surgery before 1992 (Table 4). The
higher recurrence in patients without viral or alcoholic
disease is probably due to the fact that many patients
were undiagnosed as having HCV viral infection before
1990.
Multivariate analysis of variables affecting overall survival
and tumour recurrence
At multivariate analysis, only total bilirubin level
> 1.2 mg ⁄dL, presence of multiple nodules, micro- and
macrovascular infiltration, diaphragm infiltration and
intra-operative blood transfusions were independently
correlated to survival in cirrhotic patients. Necessity of
packed red blood cells transfusion was found as the only
independent predictive factor of lower survival of
noncirrhotic patients.
Tumour recurrence was correlated with presence of
satellite nodules and surgery performed before 1992 in
Group 1, and only with patient’s age below 60 years in
Group 2 (Table 5).
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Figure 1. Overall survival of cirrhotic patients (n ¼ 308, con-
tinuous line) and noncirrhotic patients (n ¼ 135, dotted line)
undergoing liver resection for HCC (P < 0.05).
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Figure 2. Disease-free survival of cirrhotic patients (n ¼ 308,
continuous line) and noncirrhotic patients (n ¼ 135, dotted line)
undergoing liver resection for HCC (P < 0.005).
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Table 3. Univariate analysis of factors
affecting survival. *P ¼ N.S.
Variables
Cirrhotic patients
(n ¼ 308)
Noncirrhotic patients
(n ¼ 135)
5-years surv. P-value 5-year surv. P-value
Age
0–60 years 45.5% * 44% *
> 60 years 42.2% 54.8%
Sex
Male 41.4% * 55.5% *
Female 53.6% 41.6%
Tumor-related symptoms
Present 34.2% < 0.05 40.4% < 0.05
Absent 45.5% 63.9%
Preoperative ascites
Present 14.9% < 0.001 Not evaluable
Absent 46.3%
Total bilirubin level
0–1.2 mg ⁄dL 50.4% < 0.01 48.6% *
> 1.2 mg ⁄dL 32.1% 56.2%
Child–Pugh
A 48% < 0.01 51.9% *
B–C 28% 28.6%
Etiology
Viral 47.1% * 47.7% *
Alcohol 34.3% 80%
Other 38% 48.8%
HBsAg+
Positive 35.7% * 37.7% *
Negative 46.1% 54.3%
HCV+
Positive 52.4% * 53.1% *
Negative 43.3% 68%
a-FP
0–20 ng ⁄mL 52.2% < 0.01 49.3% *
> 20 ng ⁄mL 32.4% 50.8%
Tumour diameter
0–5 cm 45.1% * 57% *
> 5 cm 40.1% 58%
Multiple nodules
Single 46.7% < 0.001 52.1% *
Multiple 13.2% 42.7%
Tumour capsule
Complete 51% < 0.05 44.5% *
Absent ⁄ incomplete 40% 50.9%
Satellite nodules
Present 26% < 0.01 29.8% < 0.05
Absent 47.3% 56.9%
Microvascular invasion
Present 35.7% < 0.05 58.5% *
Absent 51.4% 42.2%
Edmonson’s grade
1–2 44.8% * 58.3% *
3–4 42% 44.3%
Year of surgery
Before 1992 34% < 0.01 36.4% < 0.01
1992 and after 50% 64.1%
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Table 4. Univariate analysis of factors
affecting recurrence. *P ¼ N.S.
Variables
Cirrhotic patients
(n ¼ 308)
Noncirrhotic patients
(n ¼ 135)
Recurrence P-value Recurrence P-value
Age
0–60 years 42% * 49% < 0.01
> 60 years 37% 24%
Sex
Male 42% < 0.05 31% *
Female 27% 31%
Tumor-related symptoms
Present 40% * 38% *
Absent 39% 23%
Preoperative ascites
Present 48% * Not evaluable
Absent 38%
Total bilirubin level
0–1.2 mg ⁄dL 39% * 31% *
> 1.2 mg ⁄dL 40% 29%
Child–Pugh
A 39% * 32% *
B–C 40% 17%
Etiology
Viral 36% < 0.01 28% *
Alcohol 9% 22%
Other 54% 33%
HBsAg+
Positive 47% * 35% *
Negative 37% 29%
HCV+
Positive 33% * 22% *
Negative 28% 27%
a-FP
0–20 ng ⁄mL 39% * 33% *
> 20 ng ⁄mL 42% 27%
Table 3. Continued
Variables
Cirrhotic patients
(n ¼ 308)
Noncirrhotic patients
(n ¼ 135)
5-years surv. P-value 5-year surv. P-value
Type of surgery
Wedge 42.9% * 29.1% *
1–2 segments 44.4% 57%
> segments 40% 44.8%
Macrovascular infiltration
Present 0% < 0.001 45.7% *
Absent 44.5% 51.1%
Diaphragm infiltration
Present 15.2% < 0.01 85.7% *
Absent 44.4% 54.4%
I.o. packed red blood cells transfusions
Yes 34.9% < 0.001 34.7% < 0.001
No 50.2% 69.5%
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Table 4. Continued
Variables
Cirrhotic patients
(n ¼ 308)
Noncirrhotic patients
(n ¼ 135)
Recurrence P-value Recurrence P-value
Tumour diameter
0–5 cm 40% * 21% *
> 5 cm 37% 33%
Multiple nodules
Single 39% * 31% *
Multiple 52% 39%
Tumour capsule
Complete 33% * 26% *
Absent ⁄ incomplete 43% 34%
Satellite nodules
Present 59% < 0.01 42% *
Absent 37% 30%
Microvascular invasion
Present 39% * 33% *
Absent 41% 26%
Edmonson’s grade
1–2 37% * 39% *
3–4 43% 31%
Year of surgery
Before 1992 57% < 0.001 37% *
1992 and after 31% 28%
Type of surgery
Wedge 35% * 13% < 0.05
1–2 segments 42% 25%
> segments 33% 45%
Macrovascular infiltration
Present 38% * 64% < 0.05
Absent 39% 27%
Diaphragm infiltration
Present 44% * 0% *
Absent 39% 33%
I.o. packed red blood cells transfusions
Yes 51% < 0.001 39% *
No 31% 25%
Table 5. Multivariate analysis of factors affecting survival and tumour recurrence. s.e. ¼ standard error. HR ¼ hazard ratio
Variables Coefficient s.e. HR P-value
Group 1 – Overall survival Bilirubin level > 1.2 mg ⁄dL )0.4520 0.1827 0.6364 < 0.05
Multiple nodules )1.1034 0.2907 0.3317 < 0.001
Microvascular invasion )0.5226 0.1949 0.5930 < 0.01
Macrovascular infiltration )1.4023 0.4507 0.2460 < 0.005
Diaphragm infiltration )1.1747 0.4401 0.3089 < 0.01
I.o. packed red blood cells transfusions )0.6113 0.1855 0.5426 < 0.001
Group 2 – Overall survival I.o. packed red blood cells transfusions )1.2681 0.3475 0.2814 < 0.001
Group 1 – Tumour recurrence Satellite nodules 0.7911 0.3483 2.2058 < 0.05
Surgery before 1992 0.9893 0.2694 2.6895 < 0.001
Group 2 – Tumour recurrence Age < 60 years 1.0880 0.4209 2.9682 < 0.01
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DISCUSSION
The first aim of this study was to assess the clinico-
pathologic differences between the groups of patients
with and without cirrhosis. We found noncirrhotic
patients to be similar to cirrhotic ones as regards age,
gender, alcoholic habit and number of HBsAg+ cases.
These findings are partially in contrast with those
reported in a recent study comparing patients with and
without liver fibrosis undergoing hepatectomy for
HCC,21 where the nonfibrotic group had higher preval-
ence of men, alcoholic abuse and lower prevalence of
positive HBsAg. In a cohort of patients almost double
that in the above-mentioned report, we could not even
confirm the data of previous studies showing that HCC
arising in a noncirrhotic liver affects subjects younger
and more frequently female than HCC with cirrho-
sis.22, 23 It must be taken into consideration that our
series includes only patients already selected for surgery
and this could lead to a bias in the study of the
demographic characteristics. With the limitation given
by the impossibility of determining HCV infection before
1990, the less frequent viral aetiology and positive HCV
status, and the better preoperative liver function of
noncirrhotic patients were consistent with previous
data.21
One interesting finding of the present study was the
tendency of HCC to be more aggressive in patients
without cirrhosis, having a larger diameter, a poorer
differentiation, a higher incidence of macrovascular
invasion than HCC with cirrhosis, and being encapsu-
lated in only 30% of cases. While the first two
characteristics are commonly reported in HCC in the
absence of cirrhosis,21, 23, 24 portal vein thrombosis and
absence of capsule were more frequently found in
cirrhotics than in noncirrhotics in a large patient
series.24 This data might have predicted a worse
outcome, but this does not come out from statistical
analysis of overall and disease-free survival.
Patients without cirrhosis underwent resection of
larger portions of the liver, with intra-operative packed
red blood cells consumption similar to that required by
cirrhotic patients. The complication and the in-hospital
mortality rates were lower in the former group. The
early mortality of less than 3% (1% in noncirrhotic
patients) and the significantly better results obtained in
both groups in the more recent years confirms the
increasing success of the surgical approach to HCC,6
which should be taken into consideration especially
when considering cirrhotic patients for possible treat-
ment.
The analysis of long-term outcome showed lower
results in cirrhotic than in noncirrhotic patients. A
lower survival and a higher tumour recurrence should
be expected in patients carrying high grade liver
fibrosis (i.e. cirrhosis) compared to those with chronic
hepatitis and less advanced fibrosis,15 however when
evaluating all patients without cirrhosis, consideration
should be given to the possibility that it is a
inhomogeneous group of different conditions, from
chronic hepatitis with stage III fibrosis18 to a morpho-
logically healthy liver. A correct methodological
approach would therefore be to distinguish different
subgroups and to separately assess the prognosis in
each of them. Even if we did not compare the clinical
and pathologic features of noncirrhotic patients
according to specific liver diseases, we found overall
survival to be similar in subjects carrying or not
carrying chronic hepatitis. The importance of liver
fibrosis on intrahepatic tumour recurrence has been
recently pointed out,25 unfortunately without a differ-
entiation in prognostic reliability among stages II, III
and IV of fibrosis. On the other hand, a further
multicentric study showed that the presence or
absence of cirrhosis itself is able to predict long-term
survival.15
In our study, the survival of patients with HCC with
cirrhosis was correlated to clinical (abnormal preoper-
ative bilirubin level), histological (presence of multiple
nodules, micro- and macrovascular invasion) and
surgical variables (intra-operative blood transfusions
and diaphragm infiltration, which probably reflected the
complexity of the procedure without predisposing to
tumour recurrence). Predictors of tumour recurrence in
the same group were the presence of satellite nodules
and resection performed before 1992. These prognostic
factors have been already reported and discussed by
others.7, 8, 11, 12, 14, 15 Conversely, the only independ-
ent variables correlated to patient survival and tumour
recurrence in noncirrhotic patients were the need for
intra-operative blood transfusions and age less than
60 years, respectively. The few studies aiming to
evaluate prognostic factors in patients undergoing liver
resection for HCC without cirrhosis based their conclu-
sions on less numerous series than the present one and
showed a number of variables significantly affecting
survival (i.e. blood losses, surgical resection margin,
tumour size, capsular invasion, presence of intrahepatic
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metastases, portal vein invasion and extent of resection)
and tumour recurrence (i.e. tumour size, portal vein
invasion and HCV infection).16, 17 Our experience
suggests that the outcome of patients with noncirrhotic
liver remains rather difficult to evaluate using the
clinicopathologic criteria of categorization commonly
adopted.7, 8, 11, 12, 14, 15 Recent studies have outlined
that HCC tends to recur more frequently in patients with
a high necro-inflammatory activity, which makes
serum transaminases a reliable method of stratifica-
tion,26, 27 probably more promising than the histolo-
gical assessment alone.
Our study also confirms the importance of avoiding
intra-operative blood losses, which mostly depends on
the surgical technique.7 The experience gained by our
group determined a significant minimization of the
intra-operative use of blood transfusions in recent
years,6 which means a direct positive impact on long-
term results.
Surgery represents a consolidated therapy for HCC
arising both with and without cirrhosis. The improved
long-term survival and the reduction in early mortality
give this procedure added value. The analysis of clinical
variables leading to higher survivals still lacks strong
and unanimously accepted indicators. Today, however,
it is possible to identify groups at higher risk of failure in
which surveillance must be extremely strict.
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